TY - JOUR T1 - <sup>18</sup>F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies JF - Anticancer Research JO - Anticancer Res SP - 2999 LP - 3005 VL - 35 IS - 5 AU - VINCENT CAMUS AU - AGATHE EDET-SANSON AU - MICHAEL BUBENHEIM AU - ANNE HITZEL AU - STÉPHANIE BECKER AU - MARION DAVID AU - ASPASIA STAMATOULLAS AU - PASCAL LENAIN AU - FABRICE JARDIN AU - NATHALIE CONTENTIN AU - MARIE LAURE FONTOURA AU - NATHALIE CARDINAEL AU - SANDRINE VAUDAUX AU - SYDNEY DUBOIS AU - HERVÉ TILLY AU - PIERRE VERA AU - STÉPHANE LEPRÊTRE Y1 - 2015/05/01 UR - http://ar.iiarjournals.org/content/35/5/2999.abstract N2 - The aim of the present study was to assess the prevalence of hyper-metabolic infection sites revealed by fluorine-18 (18F) fluorodeoxyglucose (FDG) positron-emission tomography (PET) combined with computed tomography (CT) in patients with febrile neutropenia (FN). Forty-eight consecutive patients with haematological malignancies and persistent FN (temperature ≥38°C and neutrophil count &lt;500 cells/μl for more than two days) as a consequence of intensive chemotherapy were prospectively included. Pathological FDG uptakes identified 31 foci of infections located in the lungs (n=15, 48.4 %), colon (n=4, 12.9%), pancreas (n=2, 6.5%), skin (n=3, 9.7%), ear-nose-throat area (n=5, 16.1%), central venous catheter tract (n=1, 3.2%) and gallbladder (n=1, 3.2%). These pathological FDG uptakes were observed in half of the 48 patients (n=24). Among the 38 patients with a clinical diagnosis of infection, 23 showed a pathological FDG uptake, resulting in a FDG-PET/CT sensitivity of 61% (95% CI, 43-76%). Our study confirmed the ability of FDG-PET/CT to diagnose infections in patients with persistent FN. ER -